End-stage renal disease patients on renal replacement therapy in the intensive care unit: short- and long-term outcome.
OBJECTIVE
The number of patients with end-stage renal disease has increased during the last decades. Data shows that 10% of the renal replacement therapy population in the intensive care unit are patients with end-stage renal disease. We aimed to describe the short- and long-term outcome of these patients after renal replacement therapy in the intensive care unit.


METHODS
Nationwide cohort study between the years 1995 and 2004. Follow-up up to 5 years.


METHODS
Swedish general intensive care units and Swedish hospitals.


METHODS
Eligible subjects were end-stage renal disease patients treated with renal replacement therapy in 32 Swedish general intensive care units. In total, 245 patients were studied.


METHODS
None.


RESULTS
Short- and long-term mortality was studied. Logistic regression was used to analyze short-term mortality. Long-term mortality was compared with the mortality of end-stage renal disease patients outside the intensive care unit and the mortality in the population. Diabetes and heart failure are significant risk factors for 90-day mortality, with an odds ratio of 1.9 and 2.0, respectively. The intensive care unit end-stage renal disease cohort had increased long-term mortality as compared with non-intensive care unit end-stage renal disease patients, relative risk of death 2.32 (confidence interval 1.84-2.92). A comparison with the mortality rate in the general population yielded a standardized mortality ratio of 25 (95% confidence interval: 19.6-31.4).


CONCLUSIONS
For end-stage renal disease patients in the intensive care unit, age, diabetes mellitus, and heart failure are risk factors for 90-day mortality. Long-term mortality is associated with age and heart failure. The long-term mortality of end-stage renal disease patients surviving the intensive care unit stay is significantly higher compared with end-stage renal disease patients without a known intensive care unit admission.
Bell
Max
M
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. max.bell@karolinska.se
Granath
Fredrik
F
Schön
Staffan
S
Löfberg
Erland
E
Ekbom
Anders
A
Martling
Claes-Roland
CR